Quest Diagnostics Incorporated
DGX
Ранг среди акций
#914
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Цена акции
$238.37
Рыночная капитализация
$26.31B
Изменение (1 день)
0.71%
Изменение (1 год)
29.10%
Страна
US
Торговля Quest Diagnostics Incorporated (DGX)
Категория
Healthcare
Выручка компании Quest Diagnostics Incorporated (DGX)
Выручка на Jun 2026 TTM: $11.56B
Согласно последним финансовым отчетам Quest Diagnostics Incorporated, текущая выручка компании (TTM) составляет $11.56B. В 2024 году компания получила выручку $9.87B больше, чем выручке в 2023 году, которая составила $9.25B. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Quest Diagnostics Incorporated с 2000 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $11.56B | 4.76% |
| 2025 | $11.04B | 11.78% |
| 2024 | $9.87B | 6.70% |
| 2023 | $9.25B | -6.38% |
| 2022 | $9.88B | -8.39% |
| 2021 | $10.79B | 14.32% |
| 2020 | $9.44B | 22.15% |
| 2019 | $7.73B | 2.59% |
| 2018 | $7.53B | -2.31% |
| 2017 | $7.71B | 2.58% |
| 2016 | $7.52B | 0.29% |
| 2015 | $7.49B | 0.78% |
| 2014 | $7.44B | 4.04% |
| 2013 | $7.15B | -3.20% |
| 2012 | $7.38B | -1.70% |
| 2011 | $7.51B | 1.92% |
| 2010 | $7.37B | -1.16% |
| 2009 | $7.46B | 2.84% |
| 2008 | $7.25B | 8.12% |
| 2007 | $6.70B | 6.96% |
| 2006 | $6.27B | 13.90% |
| 2005 | $5.50B | 7.36% |
| 2004 | $5.13B | 8.20% |
| 2003 | $4.74B | 15.33% |
| 2002 | $4.11B | 13.24% |
| 2001 | $3.63B | 6.04% |
| 2000 | $3.42B | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $46.34B | 300.83% |
US
|
|
| $25.11B | 117.19% |
US
|
|
| $2.71B | -76.58% |
US
|
|
| - | - |
CN
|
|
| $7.37B | -36.23% |
US
|
